Progress in adjuvant chemotherapy for breast cancer: An overview

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.

Original languageEnglish (US)
Article number195
JournalBMC Medicine
Volume13
Issue number1
DOIs
StatePublished - Aug 17 2015

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Therapeutics
Recurrence
Drug Therapy
Taxoids
Alkylating Agents
Anthracyclines
Combination Drug Therapy
Cause of Death
Neoplasms
Hormones
Gene Expression
Mortality

Keywords

  • Adjuvant chemotherapy
  • Anthracyclines
  • Breast cancer
  • Chemotherapy
  • Early breast cancer
  • Taxanes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Progress in adjuvant chemotherapy for breast cancer : An overview. / Anampa Mesias, Jesus D.; Makower, Della F.; Sparano, Joseph A.

In: BMC Medicine, Vol. 13, No. 1, 195, 17.08.2015.

Research output: Contribution to journalArticle

@article{8ce0cdc500a041e5847ce11ca840b20b,
title = "Progress in adjuvant chemotherapy for breast cancer: An overview",
abstract = "Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.",
keywords = "Adjuvant chemotherapy, Anthracyclines, Breast cancer, Chemotherapy, Early breast cancer, Taxanes",
author = "{Anampa Mesias}, {Jesus D.} and Makower, {Della F.} and Sparano, {Joseph A.}",
year = "2015",
month = "8",
day = "17",
doi = "10.1186/s12916-015-0439-8",
language = "English (US)",
volume = "13",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Progress in adjuvant chemotherapy for breast cancer

T2 - An overview

AU - Anampa Mesias, Jesus D.

AU - Makower, Della F.

AU - Sparano, Joseph A.

PY - 2015/8/17

Y1 - 2015/8/17

N2 - Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.

AB - Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.

KW - Adjuvant chemotherapy

KW - Anthracyclines

KW - Breast cancer

KW - Chemotherapy

KW - Early breast cancer

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=84939429098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939429098&partnerID=8YFLogxK

U2 - 10.1186/s12916-015-0439-8

DO - 10.1186/s12916-015-0439-8

M3 - Article

C2 - 26278220

AN - SCOPUS:84939429098

VL - 13

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 195

ER -